The Investor
06 Oct 2026, 18:04
Veeva DQS Processes Data From More Than 1 Million Clinical Trial Subjects
Veeva Systems (NYSE: VEEV) said its Data Quality System has now aggregated and cleaned clinical trial data for more than 1 million subjects across over 1,000 studies.
The platform has generated more than 500,000 automated queries, helping sponsors and research sites reduce the time and manual effort required for data reconciliation and preparation of analysis-ready datasets.
Veeva DQS automates clinical data workflows, supports risk-based quality management and uses AI to classify study data based on its purpose and criticality. The system can also integrate with Veeva CTMS to flag changes such as protocol deviations and help teams track key risk indicators.
The company said the growing volume and complexity of clinical trial data are increasing demand for automated data management tools that can accelerate study reviews and regulatory submissions.
Veeva also recently introduced its Study Builder Agent, which can configure Veeva EDC and DQS directly from a clinical study protocol, further expanding the company’s use of AI across life sciences software workflows.
Veeva Systems (NYSE: VEEV) said its Data Quality System has now aggregated and cleaned clinical trial data for more than 1 million subjects across over 1,000 studies.
The platform has generated more than 500,000 automated queries, helping sponsors and research sites reduce the time and manual effort required for data reconciliation and preparation of analysis-ready datasets.
Veeva DQS automates clinical data workflows, supports risk-based quality management and uses AI to classify study data based on its purpose and criticality. The system can also integrate with Veeva CTMS to flag changes such as protocol deviations and help teams track key risk indicators.
The company said the growing volume and complexity of clinical trial data are increasing demand for automated data management tools that can accelerate study reviews and regulatory submissions.
Veeva also recently introduced its Study Builder Agent, which can configure Veeva EDC and DQS directly from a clinical study protocol, further expanding the company’s use of AI across life sciences software workflows.
